HBM Holdings Limited (FRA:6XY)

Market Cap	1.27B +61.4%
Revenue (ttm)	134.55M +314.6%
Net Income	77.79M +3,187.7%
EPS	0.09 +2,942.0%
Shares Out	n/a
PE Ratio	16.38
Forward PE	24.08
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	1.490
Previous Close	1.490
Day's Range	1.490 - 1.490
52-Week Range	0.800 - 2.140
Beta	n/a
RSI	54.27
Earnings Date	Mar 30, 2026

About HBM Holdings

HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds and inhibits the neonatal fragment crystallizable receptor for tr...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2016
• Employees: 272
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6XY

Financial Performance

In 2025, HBM Holdings's revenue was $157.98 million, an increase of 314.63% compared to the previous year's $38.10 million. Earnings were $91.33 million, an increase of 3187.72%.

Financial numbers in USD